While a combination of TrxR1 and GSH inhibitors has the potential to cutback the mutual compensation between antioxidant systems, there is a lack of strategies that effectively exploit the dual inhibition of these antioxidant pathways in GBM. Here, TXNRD1 is linked to glioblastoma.